Ampio announces positive results from Optina trial for diabetic macular edema Ampio announced interim results from the ongoing 450 patient, dose finding, 505b2 study of OptinaTM as a treatment for Diabetic Macular Edema. This interim analysis was conducted by an Independent Data Review Committee comprised of a statistician and an ophthalmologist/retinologist, who were permitted to view the unmasked data from the trial. At least 30% of patients had reached the first 4 week time point and their clinical results were considered representative data for the trial.
News For AMPE From The Last 14 Days
Check below for free stories on AMPE the last two weeks.